Mr Spring joins Prometheus with 25 years of experience in finance and accounting. He comes most recently from Hyperion Therapeutics, where he served as senior vice president and chief financial officer. Previously, he was vice president of finance and controller of MedImmune, which was acquired by AstraZeneca for $15 billion in April 2007.
Mr Spring earned his bachelor’s degree in business administration from Monmouth College and is a certified public accountant.
Joseph Limber, president and CEO of Prometheus, said: “Mark brings a wealth of financial, operational and management experience, which will be very valuable during this important stage of our company’s growth. He is a welcome addition to our senior management team and will play a key role in planning and executing our core strategy as we continue to build on our success.”